Tambocor(R) (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter
- Category: Small Molecules
- Published on Tuesday, 26 June 2007 04:00
- Hits: 1235
TOKYO, Japan | June 26, 2007 | Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that an additional indication for Tambocor® Tablets 50 mg /100 mg (generic name: flecainide acetate) for the treatment of paroxysmal atrial fibrillation/flutter received approval in Japan.
Paroxysmal atrial fibrillation/flutter is a condition associated with tachyarrhythmia. In paroxysmal atrial fibrillation, sudden episodes of abnormal impulses occur in the atria resulting in irregular heart beats, while in paroxysmal atrial flutter, the heartbeat is in a regular rhythm, but beats rapidly. This condition causes severe palpitation and the patients with paroxysmal atrial fibrillation/flutter are also at risk of cardioembolic stroke.
In Japan, it has been reported that the number of patients with paroxysmal atrial fibrillation/flutter is estimated to be greater than one million, and also the incidence increases in parallel with age. Since the patient population is estimated to increase annually, the medical need treatment will grow in the future.
Tambocor® suppresses or prevents paroxysmal atrial fibrillation/flutter by blocking sodium channels. The effects of Tambocor® can be sustained stably with a twice-daily administration.
Eisai received approval in Japan for Tambocor® for the indication of ventricular tachyarrhythmia in June, 1991. This approval, together with Eisai's other related products including Warfarin® (anticoagulant agent) and Vasolan® (calcium antagonistic antiarrthymic treatment which controls increased heart rate in paroxysmal atrial fibrillation/flutter), will enable Eisai to make further contributions to patients by offering treatment options for managing paroxysmal atrial fibrillation/flutter.
SOURCE: Eisai Co., Ltd.